2023-05-15 07:33:47 ET
- A clinical-stage biopharmaceutical company, Fulcrum Therapeutics ( NASDAQ: FULC ) appoints Alex C. Sapir as CEO and president, effective July 1, 2023.
- Upon assuming his new role, Mr. Sapir will also join Fulcrum’s board of directors.
- Interim CEO and president, Robert Gould Ph.D., will continue to serve as a member of the board of directors following the transition.
- Mr. Sapir joined Fulcrum as special advisor to the interim president and CEO in a part-time capacity before assuming his new role.
For further details see:
Fulcrum Therapeutics appoints new executive chief